ASCRS 2024: Phase 2 trial of travoprost intracameral implant in open-angle glaucoma or ocular hypertension

Mark J. Gallardo, MD, shared some of the results from a phase 2 clinical trial of a travoprost intracameral implant in open-angle glaucoma or ocular hypertension during his ASCRS presentation.

Video Transcript

Editor's note - This transcript has been edited for clarity.

Mark J. Gallardo, MD: Today, I had the pleasure of reporting on a 2-year pivotal trial for the safety and efficacy of a new intracameral medication implant, travoprost [OTX-TIC; Ocular Therapeutix] which is a bioresorbable gel. It was a 3-month study that was extended out to 6 months. And the primary endpoints for the study were the decrease or change in IOP [intraocular pressure] from baseline at the 2-, 6-, and 12-month mark, as well as at the 8, 10, and 4 o'clock time points.

And what the data showed is there was a reduction in intraocular pressure despite there not being a preselected statistical analysis for clinical statistical significance.

Post hoc analysis did show that there was a statistically significant decline in intraocular pressure in all the diurnal time points. This specific medication is called Paxtrava, and it was the 26-microgram dosage of the implant. Like Durysta, the implant is injected and in the study all but 1 patient were injected in a clinical setting through a special 26-gauge needle that's supplied by the manufacturer.

The safety of the device was found to be very favorable and that what we saw in terms of adverse events were self-limiting and very mild in nature.